Immunic Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Immunic, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue0.000.000.000.000.000.00
Cost of Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
Operating Expenses
Research & Development80.0583.2271.2661.1238.6422.51
Selling, General & Administrative18.0116.0115.2613.3010.3314.52
Operating Expenses98.0599.2286.5291.6748.9737.03
Operating Income-98.05-99.22-86.52-91.67-48.97-37.03
Other Income/Expense
Interest Income3.393.081.040.070.060.00
Interest Expense0.000.000.000.000.000.00
Other Income/Expense-2.462.54-34.93-1.35-4.90-1.99
Income
Income Before Tax-100.51-93.61-120.41-92.95-44.02-34.93
Income Tax Expense0.000.000.000.000.000.00
Net Income-100.51-93.61-120.41-92.95-44.02-34.93
Net Income - Continuous Operations-100.51-93.61-120.41-92.950.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.00
EBITDA-97.92-99.11-86.44-91.58-48.93-34.88
EBIT-98.05-99.22-86.52-91.67-48.97-34.93
Depreciation & Amortization0.130.110.080.090.04-0.05
Earnings Per Share
Basic EPS-1.00-2.00-4.00-4.00-3.00-
Diluted EPS-1.00-2.00-4.00-4.00-3.00-5.00
Basic Shares Outstanding100.1744.3231.8223.6515.667.72
Diluted Shares Outstanding100.1744.3231.8223.6515.667.72